Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd Report issue

For profit Phase 3
Founded: Changzhou China (2016)

Organization Overview

First Clinical Trial
2020
NCT04327310
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd

Active Ingredients

Drugs in Phase 3 Trials (1)

mepolizumab (Nucala) (7 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Malaria (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 1